Health & Medical · Week of Nov 9, 2026
InMode, PAVmed report Q3 results: the week in health and medical releases
PAVmed, Photocure, Envista, IceCure, CeraVe and Aflac also issued releases, with Medicare reimbursement and capital moves as recurring themes.
Quarterly results and capital actions made up much of the week. InMode reported third quarter 2026 GAAP revenues of $92.1 million and reaffirmed its full-year outlook. PAVmed released preliminary third quarter figures. Envista priced $430 million of senior notes to repay term loan debt, and Aflac Incorporated raised its quarterly dividend 4.9%.
Medicare coverage was a common thread for diagnostics companies, with Novitas central to both cases. PAVmed says its subsidiary Lucid Diagnostics began receiving Medicare payments for EsoGuard in October after submitting claims to Novitas. Photocure says AssureMDx was not included in a Novitas Local Coverage Determination and that it continues to expect coverage in 2028. In other news, Oracle said the VA and Department of War joined its health information network, IceCure Medical received a patent in China, and CeraVe announced a film marketing partnership.

InMode Ltd.
InMode Reports Third Quarter 2026 Financial Results: Quarterly GAAP Revenues of $92.1 Million; Reaffirms Full-Year 2026 Financial Outlook
InMode reported third quarter 2026 GAAP revenues of $92.1 million, compared with $93.2 million a year earlier, and GAAP net income of $18.9 million, or $0.32 per diluted share. The company reaffirmed 2026 revenue guidance of $365 million to $375 million and says its GAAP operating margin fell to 19% from 22%, mainly due to a North American sales team restructuring.

PAVmed Inc.
PAVmed Provides Business Update and Reports Preliminary Third Quarter 2026 Financial Results
PAVmed reported preliminary third quarter results, including a non-GAAP adjusted net loss of approximately $1.2 million, and says subsidiary Lucid Diagnostics began receiving Medicare payments for its EsoGuard test in October. Lucid performed 2,871 EsoGuard tests in 3Q26, and the company says October was a record month with more than 1,800 tests.

Envista Holdings Corporation
Envista Announces Pricing of $430 Million of Senior Notes
Envista Holdings Corporation priced $430 million of 6.250% Senior Notes due 2033 at 99.482% of principal amount, with closing expected on or about November 24, 2026. The company says net proceeds are intended to repay obligations under its U.S. dollar term loan A facility, pay related fees and costs, and for general corporate purposes.

Aflac Incorporated
Aflac Incorporated Announces 4.9% Increase in the First Quarter 2027 Dividend
Aflac Incorporated declared a first quarter 2027 dividend of $0.64 per share, a 4.9% increase over the previously declared fourth quarter 2026 dividend, payable on March 1, 2027 to shareholders of record on February 17, 2027. Chairman and CEO Daniel P. Amos cited 44 consecutive years of dividend increases.

IceCure Medical
IceCure Granted New Patent in China for Its Cryogenic System Connector, Expanding Its Global IP Portfolio
IceCure Medical said China's National Intellectual Property Administration granted it a patent covering a connector used in its cryogenic technology platform. The grant follows the company's September 2026 approval to market ProSense and its associated cryoprobes in China, and IceCure says its portfolio now contains 42 patents.

Oracle
Department of Veterans Affairs and Department of War Go-Live on Oracle Health Information Network to Expand Nationwide Health Information Exchange
Oracle Health said the Department of Veterans Affairs and Department of War began participating in Oracle Health Information Network, a Qualified Health Information Network under TEFCA, on November 5, 2026. According to the company, participation gives VA and DoW clinicians access to a broader range of patient information from participating community providers.

CeraVe
CeraVe Becomes "The Official Moisturizer of Arrakis" in First-Ever Film Partnership with DUNE: PART THREE
CeraVe announced a global marketing partnership with Warner Bros. Pictures and Legendary Pictures' Dune: Part Three, which it describes as its first official film partnership. The campaign centers on CeraVe Moisturizing Cream and runs through the film's theatrical release, which begins December 18, 2026 in North America.
Photocure
Photocure Provides Update on AssureMDx and Anticipated Medicare Coverage Timeline
Photocure said its AssureMDx bladder cancer test was not included in a Novitas Local Coverage Determination dated November 6, 2026, and that it expects Medicare coverage in line with its original 2028 assumption. The company says a CMS pricing determination is expected before year-end 2026, and it still expects initial AssureMDx revenue in 2027.
This roundup is written with AI assistance from the press releases listed above, using only what they state. The releases are the companies' own announcements, not BlessFeed reporting.